Improvements in health-related quality of life in people with cystic fibrosis ≥6 years of age treated with vanzacaftor/tezacaftor/deutivacaftor
VNZ/TEZ/D-IVA was associated with higher HRQoL in adolescents and adults aged ≥14 years compared to ELX/TEZ/IVA, with largest changes in participants with F/MF genotypes, and in children aged 6-11 years compared to ELX/TEZ/IVA baseline. These results highlight potential HRQoL benefits from greater CFTR function restoration with VNZ/TEZ/D-IVA.
Authors
- Bradley S. Quon (ORCID: https://orcid.org/0000-0003-1785-3870)
- Yifan Xue (ORCID: https://orcid.org/0000-0002-7818-0916)
- Sarah C. Conner (ORCID: https://orcid.org/0000-0002-0929-9948)
- Teja Thorat (ORCID: https://orcid.org/0000-0003-2856-752X)
- Yiyue Lou (ORCID: https://orcid.org/0000-0003-4098-780X)
- Lisa J. McGarry (ORCID: https://orcid.org/0000-0003-3454-9184)
- Chen Mo (ORCID: https://orcid.org/0000-0003-1299-2302)
- Claire Wainwright (ORCID: https://orcid.org/0000-0001-8389-3809)
- J. Duckers (ORCID: https://orcid.org/0000-0003-3004-279X)
- Ling Zhu (ORCID: https://orcid.org/0009-0006-8106-4250)
Institutions
- Cardiff and Vale University Health Board (GB)
- University of British Columbia (CA)
- The University of Queensland (AU)
- St. Paul's Hospital (CA)
- Vertex Pharmaceuticals (United States) (US)
Publication Details
- Journal
- Journal of Cystic Fibrosis
- Published
- 2025-12-05
- DOI
- https://doi.org/10.1016/j.jcf.2025.11.014
- Primary Topic
- Cystic Fibrosis Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Vertex Pharmaceuticals